CellSeed

CellSeed Debt/EBITDA

The Total Debt to EBITDA Ratio of CellSeed (7776.T) as of Oct 27, 2026 is -0.13. In the previous year, Total Debt to EBITDA Ratio was -0.17 — a change of -25.19% (higher).

Debt/EBITDA

-0.13

YoY

-25.19%

Last updated:

Total Debt to EBITDA Ratio of CellSeed is 2025 -0.13 . Total Debt to EBITDA Ratio of CellSeed was 2024 -0.17 . It decreases by -25.19% higher compared to the previous year.

The CellSeed Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2020
-0.21 JPY
Jan 1, 2021
-0.18 JPY
Jan 1, 2022
-0.21 JPY
Jan 1, 2023
-0.22 JPY
Jan 1, 2024
-0.17 JPY
Jan 1, 2025
-0.13 JPY
The CellSeed Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.13-25.19%
-0.17-21.65%
-0.22+1.84%
-0.21+20.54%
-0.18-15.08%
-0.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Total Debt to EBITDA Ratio of CellSeed is -0.13 in 2025.

Total Debt to EBITDA Ratio of CellSeed changed from -0.17 to -0.13, representing a -25.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio CellSeed since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's CellSeed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CellSeed

All Key Metrics — CellSeed